- Home
- XOMAP vs DVAX Comparison
XOMAP vs DVAX Comparison
Compare XOMAP & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- DVAX
- Stock Information
- Founded
- XOMAP N/A
- DVAX 1996
- Country
- XOMAP United States
- DVAX United States
- Employees
- XOMAP 13
- DVAX N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- XOMAP Health Care
- DVAX Health Care
- Exchange
- XOMAP Nasdaq
- DVAX Nasdaq
- Market Cap
- XOMAP N/A
- DVAX N/A
- IPO Year
- XOMAP N/A
- DVAX 2004
- Fundamental
- Price
- XOMAP $25.60
- DVAX $9.99
- Analyst Decision
- XOMAP
- DVAX Buy
- Analyst Count
- XOMAP 0
- DVAX 4
- Target Price
- XOMAP N/A
- DVAX $26.25
- AVG Volume (30 Days)
- XOMAP N/A
- DVAX 1.8M
- Earning Date
- XOMAP N/A
- DVAX 08-05-2025
- Dividend Yield
- XOMAP N/A
- DVAX N/A
- EPS Growth
- XOMAP N/A
- DVAX N/A
- EPS
- XOMAP N/A
- DVAX N/A
- Revenue
- XOMAP N/A
- DVAX $294,620,000.00
- Revenue This Year
- XOMAP N/A
- DVAX $21.18
- Revenue Next Year
- XOMAP N/A
- DVAX $16.83
- P/E Ratio
- XOMAP N/A
- DVAX N/A
- Revenue Growth
- XOMAP N/A
- DVAX 24.76
- 52 Week Low
- XOMAP N/A
- DVAX $9.22
- 52 Week High
- XOMAP N/A
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- XOMAP 47.92
- DVAX 46.00
- Support Level
- XOMAP $25.65
- DVAX $9.89
- Resistance Level
- XOMAP $25.70
- DVAX $10.68
- Average True Range (ATR)
- XOMAP 0.06
- DVAX 0.36
- MACD
- XOMAP -0.00
- DVAX 0.05
- Stochastic Oscillator
- XOMAP 22.85
- DVAX 31.00
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.